Showing results (11-20 of 37) with videos related to
Sort By:
Pageof 4
Nature|February 18, 2015
Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformationTea Pemovska, Eric Johnson, Mika Kontro, et al.Cellular and Molecular Life Sciences : CMLS|November 1, 2021
Vascular adhesion protein-1 defines a unique subpopulation of human hematopoietic stem cells and regulates their proliferationImtiaz Iftakhar-E-Khuda, Alberto Pessia, Shuyu Zheng, et al.Scientific Reports|June 6, 2014
Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapiesBhagwan Yadav, Tea Pemovska, Agnieszka Szwajda, et al.Patient Education and Counseling|July 8, 2023
Personalizing precision medicine: Patients with AML perceptions about treatment decisionsÅsa Grauman, Mika Kontro, Karl Haller, et al.NPJ Digital Medicine|October 6, 2025
Digital twin models for predicting venetoclax and azacitidine-induced neutropenia in patients with acute myeloid leukemiaYue Zhang, Jonathan Martinez, Bahar Tercan, et al.Cancer Research|May 12, 2025
A Machine Learning-Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid LeukemiaYingjia Chen, Liye He, Aleksandr Ianevski, et al.Oncotarget|January 18, 2015
Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemiaKati Kämpjärvi, Tiina M Järvinen, Tuomas Heikkinen, et al.Human Mutation|January 6, 2017
Somatic MED12 Nonsense Mutation Escapes mRNA Decay and Reveals a Motif Required for Nuclear EntryTuomas Heikkinen, Kati Kämpjärvi, Salla Keskitalo, et al.Basic & Clinical Pharmacology & Toxicology|April 28, 2025
Capillary Sampling Enables Venetoclax Concentration Measurement in Acute Myeloid Leukaemia Within Academic Multicentre TrialSari Kytölä, Mika Kurkela, Johanna I Kiiski, et al.Hemasphere|January 14, 2026
Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacyIda Vänttinen, Joseph Saad, Tanja Ruokoranta, et al.Pageof 4